Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Colchicine Titration Guided by Hs-CRP Targets on Cardiovascular Events in Very-High-Risk Coronary Heart Disease Patients After PCI: A Multicenter, Randomized, Open-Label, Noninferiority Trial

NCT07920133 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.

NCT NCT07920133 Not yet recruiting Not applicable 1,768 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07920133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, 1,768 participants (estimated). Lead sponsor Sir Run Run Shaw Hospital; China. Primary measure: Major Adverse Cardiovascular Events Through 18 Months.

How it compares

370 similar trials: same condition (Atherosclerosis) and phase

Enrollment

This trial
1,768
Middle half
40 to 218
Median
94
Trials with a value
370

Months from start to completion

This trial
73
Middle half
19.6 to 55.1
Median
34.5
Trials with a value
364

Sites

This trial
1
Middle half
1 to 1
Median
1
Trials with a value
337
Posted results or a linked paper 54% 198 of 370 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Colchicine Titration Guided by Hs-CRP Targets on Cardiovascular Events in Very-High-Risk Coronary Heart Disease Patients After PCI: A Multicenter, Randomized, Open-Label, Noninferiority Trial
Lead sponsor
Sir Run Run Shaw Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 31, 2032
Enrollment
1,768 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Atherosclerosis, Coronary Artery Disease

Registry terms: atherosclerotic cardiovascular disease (ascvd), residual inflammatory risk

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Sir Run Run Shaw Hospital

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Standard hs-CRP Target (1.0 to <2.0 mg/L) Experimental Colchicine (Colcrys®)
Show registry wording

Colchicine 0.25 mg orally once daily at initiation, with hs-CRP-guided adjustments to target 1.0 to \<2.0 mg/L. At 1 month, reduce to 0.25 mg every other day if hs-CRP \<1.0 mg/L; maintain 0.25 mg daily if 1.0 to \<2.0 mg/L; or, if tolerated, increase to 0.5 mg daily if ≥2.0 mg/L. If the target remains unmet after one month at 0.5 mg daily, stop protocol-directed colchicine and continue endpoint/safety follow-up. Dose reduction or discontinuation is permitted for adverse reactions.

Intensive hs-CRP Target (<1.0 mg/L) Active comparator Colchicine (Colcrys®)
Show registry wording

Colchicine 0.25 mg orally once daily at initiation, with hs-CRP-guided adjustments to target \<1.0 mg/L. At 1 month, maintain 0.25 mg daily if hs-CRP \<1.0 mg/L; otherwise, if tolerated, increase to 0.5 mg daily. If the target remains unmet after one month at 0.5 mg daily, stop protocol-directed colchicine and continue endpoint/safety follow-up. Dose reduction or discontinuation is permitted for adverse reactions.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Major Adverse Cardiovascular Events Through 18 Months From randomization through 18 months
Show registry wording

Time to first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or ischemia-driven coronary revascularization. The primary noninferiority comparison is the hazard ratio for the standard hs-CRP target strategy versus the intensive hs-CRP target strategy, with a prespecified margin of 1.30; events are adjudicated by an independent blinded clinical events committee.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Colchicine 41 Orange Book patentsPatent cliff December 20, 2037 (Orange Book patent)
    • US 10226423; expires December 20, 2037; assignee RxOmeg Therapeutics LLC
    • US 10383820; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
    • US 10383821; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
    • US 12274751; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
    • US 12514819; expires November 22, 2036; assignee not stated
    • +36 more patents

Lead sponsor's other trials

Sir Run Run Shaw Hospital, most recent start first.

Similar trials

Same condition (Atherosclerosis) and phase, most recent start first.